- Home
- AEON vs VTGN Comparison
AEON vs VTGN Comparison
Compare AEON & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.89
HOLD
Current Price
$0.60
Company Overview
Basic Information| Metric | AEON | VTGN |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8M | 21.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AEON | VTGN |
|---|---|---|
| Price | $0.89 | $0.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.20 | $0.90 |
| AVG Volume (30 Days) | 69.5K | ★ 448.3K |
| Earning Date | 05-13-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $0.43 |
| 52 Week High | $1.45 | $5.14 |
Technical Indicators
Market Signals| Indicator | AEON | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 52.05 |
| Support Level | $0.87 | $0.57 |
| Resistance Level | $1.12 | $0.66 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 12.07 | 66.09 |
Price Performance
Historical Comparison AEON
VTGN
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.